| 437 | 9 | 18 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：观察清肝活血方（Qing Gan Huo Xue Prescription,QGHXP）用于酒精性肝硬化（alcoholic liver cirrhosis,ALC）湿热瘀结证患者治疗的临床疗效。方法：将符合ALC诊断的69例患者随机分为两组，中药组35例，予以中药清肝活血方；对照组34例，予以多烯磷脂酰胆碱胶囊456 mg tid po；疗程均为24周。观察指标：临床症状疗效；肝酶水平（血清AST、γ-GT、ALT和ALP）；瞬时弹性成像技术（transient elastrography,TE）FibroTouch检测肝硬度测量值（liver stiffness measurement,LSM）,APRI评分（AST to platelet ratio index,APRI）、FIB-4指数（fibrosis-4 index/indices,FIB-4 index/indices）和Maddrey判别函数评估肝功能。结果：中药组和对照组临床症状疗效总有效率分别为85.70%和61.80%，中药组优于对照组（P=0.024）；肝酶水平：治疗后中药组AST、ALP、γ-GT、ALT较治疗前降低，且均低于对照组（P<0.05）。治疗后中药组LSM低于对照组（14.19±1.49）vs(15.06±1.24)(P<0.05)，中药组APRI评分、FIB-4指数和Maddrey判别函数低于对照组（P<0.05）。结论：QGHXP用于治疗ALC湿热瘀结证患者可缓解患者临床症状、肝酶水平，并改善ALC肝功能和预后。
Abstract：Objective:To evaluate the efficacy of Qing Gan Huo Xue Prescription(QGHXP)in the treatment of patients with alcoholic liver cirrhosis(ALC)of damp and heat stasis syndrome. Methods:A total of 69 patients with ALC were randomly divided into TCM group(n=35)and control group(n=34). The TCM group was given QGHXP 1 pack TID orally. Control group received polyene phosphatidylcholine capsule 456 mg TID for 24 weeks. The observation measurements are symptom efficacy rate,serum level of liver enzyme,and non-invasive liver cirrhosis evaluation,including liver stiffness measurement(LSM)examininged by FibroTouch,APRI score,FIB-4 index and Maddrey discriminant function. Results:The symptom efficacy rate of the experimental group and the control group was 85.70% and 61.80%(P=0.024). Liver enzyme levels(serum ALP,γ-GT,AST and ALT)of TCM group were lower than those of control group(P<0.05). LSM of TCM group was reduced after treatment,and was significant lower than control group(14.19±1.49)vs.(15.06±1.24)(P<0.05). The APRI scores,FIB-4 index and Maddrey discriminant functions of TCM group were lower than those of control group(P<0.05). Conclusion:QGHXP is an effective alternative for the treatment of damp and heat stasis syndrome of ALC in improving liver function and clinical symptoms.
1 Singal AK,Bataller R,Ahn J,et al.ACG clinical guideline:Alcoholic liver disease[J].Am J Gastroenterol,2018,113(2):175.
2 Osna NA,Donohue Jr TM,Kharbanda KK.Alcoholic liver disease:Pathogenesis and current management[J].Alcohol Res,2017,38(2):147.
3 Mellinger JL.Epidemiology of alcohol use and alcoholic liver disease[J].Clin Liver Dis(Hoboken),2019,13(5):136.
4 Crabb DW,Im GY,Szabo G,et al.Diagnosis and treatment of alcohol-associated liver diseases:2019 practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology,2020,71(1):306-333.
5中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南（2018年更新版）[J].实用肝脏病杂志，2018,21(2):170-176.
6 Cho Y,Park YS,Kim HY,et al.Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid(GRACIAH trial):Study protocol for a randomized controlled trial[J].Trials,2018,19(1):1-8.
7王育群，季光，张玮，等.清肝活血方治疗酒精性肝病的随机对照临床研究[J].北京中医杂志，2002,21(4):195-198．
8季光，王育群，曹承楼，等.清肝活血方治疗酒精性肝病的临床研究[J].中国中西医结合杂志，2004,24(1):13-16．
9 Wu T,Chen JM,Xiao TG,et al.Qinggan Huoxue Recipe suppresses epithelial-to-mesenchymal transition in alcoholic liver fibrosis through TGF-β1/Smad signaling pathway[J].World J Gastroenterol,2016,22(19):4695.
10 Wu T,Liu T,Zhang L,et al.Chinese medicinal formula,Qinggan Huoxue Recipe protects rats from alcoholic liver disease via the lipopolysaccharide-Kupffer cell signal conduction pathway[J].Exp Ther Med,2014,8(2):363-370.
11陈珺明，王磊，邢练军，等.清肝活血方对酒精性肝纤维化大鼠基质金属蛋白酶的调控作用[J].中国中西医结合杂志，2011,31(11):1538-1544.
12郑莜萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002.
13李军祥，陈誩，姚树坤.肝纤维化中西医结合诊疗共识意见（2017年）[J].中国中西医结合消化杂志，2017,25(12):895-900.
14 El-Omar EM,Banerjee S,Wirz A,et al.The Glasgow Dyspepsia Severity Score-a tool for the global measurement of dyspepsia[J].Eur J Gastroenterol Hepatol,1996,8(10):967-971．
15瞬时弹性成像技术诊断肝纤维化专家共识（2018年更新版）[J].中华肝脏病杂志，2019,27(3):182-191.
16 Li C,Li R,Zhang W.Progress in non-invasive detection of liver fibrosis[J].Cancer Biol Med,2018,15(2):124.
17 Hagan M,Asrani SK,Talwalkar J.Non-invasive assessment of liver fibrosis and prognosis[J].Expert Rev Gastroenterol Hepatol,2015,9(10):1251-1260.
18 Sterling RK,Lissen E,Clumeck N,et al.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection[J].Hepatology,2006,43:1317-1325.
19 Tseng TC,Liu CJ,Su TH,et al.Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection[J].Aliment Pharmacol Ther,2018,47(11):1480-1489.
20 Allenson K,Roife D,Kao LS,et al.Estimation of hepatocellular carcinoma mortality using aspartate aminotransferase to platelet ratio index[J].J Gastrointest Oncol,2020,11(2):291.
21 Peleg N,Issachar A,Sneh-Arbib O,et al.AST to platelet ratio index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease[J].Dig Liver Dis,2017,49(10):1133-1138.
基本信息:
DOI：10.13210/j.cnki.jhmu.20210905.001
中图分类号:R259
引用信息:
[1]潘洁露,邢练军,张济,等.清肝活血方治疗酒精性肝硬化湿热瘀结证的随机对照临床试验[J].海南医学院学报,2022,28(08):579-584.DOI:10.13210/j.cnki.jhmu.20210905.001.
基金信息:
上海市卫健委中医药科研课题（2018LP033）; 上海市卫健委、上海市医药卫生发展基金会医苑新星青年医学人才专科全科项目（沪卫人事[2020]087号）~~
2021-09-06
2021-09-06
2021-09-06